365 related articles for article (PubMed ID: 30977520)
1. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
Silberstein SD; McAllister P; Ning X; Faulhaber N; Lang N; Yeung P; Schiemann J; Aycardi E; Cohen JM; Janka L; Yang R
Headache; 2019 Jun; 59(6):880-890. PubMed ID: 30977520
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
3. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
4. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Igarashi H; Hirata K; Takeshima T; Ning X; Shima T; Ishida M; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1092-1101. PubMed ID: 34324700
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Tatsuoka Y; Imai N; Ning X; Ishida M; Nagano K; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1102-1111. PubMed ID: 34323290
[TBL] [Abstract][Full Text] [Related]
9. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
Sakai F; Suzuki N; Ning X; Ishida M; Usuki C; Iba K; Isogai Y; Koga N
Drug Saf; 2021 Dec; 44(12):1355-1364. PubMed ID: 34687446
[TBL] [Abstract][Full Text] [Related]
11. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
12. Fremanezumab for the Preventive Treatment of Chronic Migraine.
Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
[TBL] [Abstract][Full Text] [Related]
14. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
Winner PK; Spierings ELH; Yeung PP; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Headache; 2019 Nov; 59(10):1743-1752. PubMed ID: 31675102
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
Diener HC; McAllister P; Jürgens TP; Kessler Y; Ning X; Cohen JM; Campos VR; Barash S; Silberstein SD
Cephalalgia; 2022 Jul; 42(8):769-780. PubMed ID: 35331009
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.
Silberstein SD; Rapoport AM; Loupe PS; Aycardi E; McDonald M; Yang R; Bigal ME
Headache; 2019 Mar; 59(3):383-393. PubMed ID: 30450545
[TBL] [Abstract][Full Text] [Related]
18. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
19. Fremanezumab for the prevention of chronic and episodic migraine.
Lionetto L; Cipolla F; Guglielmetti M; Martelletti P
Drugs Today (Barc); 2019 Apr; 55(4):265-276. PubMed ID: 31050694
[TBL] [Abstract][Full Text] [Related]
20. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
